Scienmag

OCTOBER 6, 2020

Scientists in the US and UK publish first in-depth look at how CD4+ T cells fight SARS-CoV-2 Credit: NIAID LA JOLLA–As scientists around the world develop life-saving COVID-19 vaccines and therapies, many are still wondering exactly why the disease proves deadly in some people and mild in others.

Scientist 40

Scientist Vaccination Vaccine Development 40

Scienmag

MARCH 5, 2021

Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

Scientist 74

Scientist Antibody Research Allergies 74

Scienmag

SEPTEMBER 1, 2020

Genetic analysis of sequences from more than 27,000 individuals infected with the coronavirus that causes COVID-19 reveals that the virus has mutated minimally since December 2019, suggesting one vaccine would be sufficient to combat global infections.

Genetic Analysis 70

Genetic Analysis Vaccination Vaccine Genetics 70

Scienmag

JANUARY 10, 2021

January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.

Vaccination 59

Vaccination Vaccine Antibody Scientist 59

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, to prevent COVID-19 in individuals 18 years of age and older. The terms of the EUA allow use of the vaccine while more data are gathered.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

SEPTEMBER 3, 2020

A team at the George Washington University Vaccine Research Unit has developed a controlled human hookworm infection model, accelerating the development of human hookworm vaccines WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model (..)

Vaccination 68

Vaccination Vaccine Research Development 68

Scienmag

JUNE 18, 2021

Recent advancements allow for novel approaches against an old enemy Scientists from the Walter Reed Army Institute of Research and Naval Medical Research Center partnered with researchers at the University of Pennsylvania and Acuitas Therapeutics to develop a novel vaccine based on mRNA technology that protects against malaria in animal models, publishing (..)

Vaccination 41

Vaccination Vaccine Scientist Development 41

Drug Discovery World

JANUARY 31, 2024

As such, the SLAS award opportunities, such as the SLAS Tony B Travel Award Program and the Student Poster Award, show the organisation’s commitment to providing a platform from the very beginning of a researcher or scientist’s career, as well as the importance of keeping new ideas pride of place.

Gene Therapy 52

Gene Therapy Allergies Scientist Gene 52

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

XTalks

DECEMBER 7, 2020

Past Few Weeks Herald Good News on the Vaccine Front. First came the news from Pfizer and its German partner BioNTech that their mRNA vaccine was 90 percent effective in preventing symptomatic COVID-19 disease. In their trial, some 30,000 patients received either two doses of Moderna’s mRNA-1273 vaccine 28 days apart or placebo.

Vaccination 52

Vaccination Vaccine Development Drugs 52

Scienmag

JULY 26, 2021

What The Study Did: Researchers examined the safety of the second dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines in patients who experienced an allergic reaction to the first dose. Authors: Kimberly G. Blumenthal, M.D., of Massachusetts General Hospital in Boston, is the corresponding author.

Vaccination 75

Vaccination Vaccine Research Scientist 75

Scienmag

MAY 3, 2021

Researchers who elucidated key functions of RNA, the workhorse molecule of cells, will be honored in October The 2021 Warren Alpert Foundation Prize has been awarded to scientists Lynne Maquat and Joan Steitz for seminal discoveries in the biology and function of RNA, the workhorse molecule of cells.

RNA 41

RNA Scientist Research Allergies 41

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. The two drugs combined with radiation cleared the brain metastases in 75% of the animals, as reported in the journal Science Translational Medicine.

Vaccination 53

Vaccination Vaccine Research Trials 53

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccination 61

Scienmag

DECEMBER 4, 2020

Findings are important for vaccines, therapeutics and public health strategies to combat the COVID-19 pandemic Boston, Mass.

Vaccination 41

Vaccination Vaccine Research Scientist 41

Scienmag

JANUARY 25, 2021

OHSU study has important implications for vaccines, diagnosis of COVID-19 A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.

Antibody 40

Antibody Scientist Vaccination Vaccine 40

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company.

Immune Response 52

Immune Response Protein Medicine Genetics 52

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

Scienmag

AUGUST 17, 2020

. — University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. Existing antibodies may also limit the benefit a patient receives from an anti-opioid vaccine, the […].

Antibody 50

Antibody Scientist Vaccination Vaccine 50

Scienmag

MAY 13, 2021

Scientists at the Ragon Institute of MGH, MIT and Harvard discover epigenetic changes unique to B cells and B cell subtypes BOSTON – B cells are the immune cells responsible for creating antibodies, and most B cells, known as B2 cells, produce antibodies in response to a pathogen or a vaccine, providing defense and immunity […].

Antibody 40

Antibody Scientist Vaccination Vaccine 40

Bioengineer

JULY 15, 2021

associate professor of human oncology in the University of Wisconsin School of Medicine and Public Health, and their colleagues designed a study to give mice with immunologically cold metastatic cancers varying doses of targeted radionuclide therapy alongside immunotherapy. About the University of Pittsburgh School of Medicine.

Medicine 52

Medicine Clinical Trials Clinical Trials Scientist 52

Scienmag

MAY 26, 2021

Credit: HKUST In a new study, scientists at The Hong Kong University of Science and Technology (HKUST) have revealed that most T cell epitopes known to be targeted upon natural infection are seemingly unaffected by current SARS-CoV-2 variants.

Scientist 96

Scientist Research Allergies Vaccination 96

Scienmag

SEPTEMBER 14, 2020

Thanks to the sniffling noses, coughs, and colds that accompany the colder months of the year, we are all too familiar with the seasonal patterns of some respiratory viruses.

Scientist 42

Scientist Allergies Vaccination Vaccine 42

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

APRIL 4, 2022

If approved, Dupixent would be the first medicine available in the U.S. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. indicated to treat eosinophilic esophagitis There are approximately 160,000 patients in the U.S. In the U.S.,

Medicine 52

Medicine Trials Allergies FDA Approval 52

Scienmag

JUNE 3, 2021

FDA-approved drugs or experimental drugs with ample health data could be rapidly tested in humans for treatment of COVID-19 Credit: Scripps Research June 3, 2021 – LA JOLLA, CA–Mining the world’s most comprehensive drug repurposing collection for COVID-19 therapies, scientists have identified 90 existing drugs or drug candidates with (..)

FDA Approval 57

FDA Approval Drugs Scientist Research 57

The Pharma Data

FEBRUARY 13, 2022

If approved, Dupixent will be the first biologic medicine available in the U.S. Dupixent remains the only biologic medicine approved for patients 6 years of age and older in this indication. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible.

Medicine 40

Medicine Genetics Antibody Allergies 40

The Pharma Data

FEBRUARY 12, 2022

Early in 2021, prior to the identification of the Omicron variant, Lilly scientists were already working to develop bebtelovimab as a broadly neutralizing antibody that could be used to fight a highly mutated variant, should one emerge,” said Daniel Skovronsky, M.D., About BLAZE-4. Across the globe,?Lilly?employees

Antibody 40

Antibody Trials Clinical Trials Clinical Trials 40

Drug Discovery World

FEBRUARY 3, 2023

A research group from the National Institutes of Health has successfully developed a vaccine against Sudan virus (SUDV) based on the licensed Ebola virus (EBOV) vaccine. SUDV, identified in 1976, is one of the four viruses known to cause human Ebolavirus disease.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

The Pharma Data

FEBRUARY 19, 2022

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. About Regeneron.

Genetics 40

Genetics Antibody Trials Medicine 40

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 15, 2021

One French scientists concluded that this ingredient contains something which stimulates the growth of cancerous tumors! Page 61 – This beverage is allowed to contain a drop of white pus (dead blood cells) by the FDA, and has been linked to asthma, allergies, diabetes, heart disease, colitis, Crohns disease and other deadly diseases.

Doctors 52

Doctors Doctor Containment Allergies 52

The Pharma Data

APRIL 14, 2021

Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S.

Antibody 52

Antibody Protein Scientist Development 52

The Pharma Data

APRIL 16, 2021

“Lilly moved quickly to make bamlanivimab alone available as a potentially lifesaving medicine at a time when Americans were hardest hit by COVID-19,” said Daniel Skovronsky, M.D., However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it.

Antibody 52

Antibody Development Medicine Protein 52

The Pharma Data

MAY 4, 2021

This donation furthers both Lilly and Direct Relief’s charitable goal of providing access to COVID-19 treatments to patients in need by providing these medicines free of charge to low- and lower-middle-income countries. Ricks , Lilly chairman and CEO. It was identified from a blood sample taken from one of the first U.S.

Antibody 52

Antibody Medicine FDA Approval Licensing 52